Furthermore, the clinical development of PARP inhibitors has demonstrated that this understanding can identify therapeutic targets, inhibitors of which might realistically be combined with irinotecan to yield clinically significant improvements in tumour response rates. The gene discussed is PARP1; the disease is neoplasm.